The novel antisense Bcl-2 inhibitor SPC2996 causes rapid leukemic cell clearance and immune activation in chronic lymphocytic leukemia. (Q54385532)

29 May 2018

title

The novel antisense Bcl-2 inhibitor SPC2996 causes rapid leukemic cell clearance and immune activation in chronic lymphocytic leukemia. (English)

1 reference

29 May 2018

0 references

1 reference

J Dürig

1

1 reference

29 May 2018

U Dührsen

2

1 reference

29 May 2018

L Klein-Hitpass

3

1 reference

29 May 2018

J Worm

4

1 reference

29 May 2018

J B Rode Hansen

5

1 reference

29 May 2018

H Ørum

6

1 reference

29 May 2018

M Wissenbach

7

1 reference

29 May 2018

publication date

1 March 2011

1 reference

29 May 2018

published in

Leukemia

1 reference

29 May 2018

volume

25

1 reference

29 May 2018

issue

4

1 reference

29 May 2018

page(s)

638-647

1 reference

29 May 2018

https://scigraph.springernature.com/pub.10.1038/leu.2010.322

exact match

0 references

cites work

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.322

Bcl-2 and apoptosis in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.322

Bcl-2 antisense therapy in B-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.322

Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.322

5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.322

Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.322

Antisense and nonantisense effects of antisense Bcl-2 on multiple roles of Bcl-2 as a chemosensitizer in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.322

The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.322

Modulation of CpG oligodeoxynucleotide-mediated immune stimulation by locked nucleic acid (LNA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.322

Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.322

Locked nucleic acid as a novel class of therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.322

Gene expression signatures separate B-cell chronic lymphocytic leukaemia prognostic subgroups defined by ZAP-70 and CD38 expression status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.322

Efficient nucleofection of primary human B cells and B-CLL cells induces apoptosis, which depends on the microenvironment and on the structure of transfected nucleic acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.322

Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.322

CpG DNA activation and plasma-cell differentiation of CD27- naive human B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.322

In vitro and in vivo activation induces BAFF and APRIL expression in B cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.322

CpG drives human transitional B cells to terminal differentiation and production of natural antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.322

Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.322

Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.322

Isolation of microarray-grade total RNA, microRNA, and DNA from a single PAXgene blood RNA tube

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.322

Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.322

G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.322

Expression and function of toll like receptors in chronic lymphocytic leukaemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.322

Toll-like receptors on B-CLL cells: expression and functional consequences of their stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.322

Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.322

A phase I/II trial of TLR-7 agonist immunotherapy in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.322

inferred from DOI database lookup

7 January 2021

based on heuristic

A novel nonobese diabetic/severe combined immunodeficient xenograft model for chronic lymphocytic leukemia reflects important clinical characteristics of the disease

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.322

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/LEU.2010.322

1 reference

29 May 2018

PubMed ID

21358717

1 reference

29 May 2018